Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Knight Therapeutics Enters Exclusive License Agreement With Amneal Pharmaceuticals For IPX203 Granting Knight Exclusive Rights To Seek Regulatory Approval And Commercialize IPX203 In Canada And Latin America

Author: Benzinga Newsdesk | January 25, 2024 08:31am

Posted In: AMRX TSX:GUD